Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19t-haNK
- Development stage
- Phase 2
- Lead developer
- ImmunityBio
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD19t-haNK is an investigational, allogeneic natural killer (NK) cell therapy engineered to express a chimeric antigen receptor (CAR) targeting the B-lymphocyte antigen CD19 and a high-affinity variant of the Fc gamma receptor III-A (CD16). Derived from the parental NK-92 cell line, these cells are designed to enhance direct cytotoxicity against cancer cells expressing CD19 and to augment antibody-dependent cellular cytotoxicity (ADCC) in combination with monoclonal antibodies. The therapy is being developed as an off-the-shelf product for use in patients with relapsed or refractory B-cell malignancies such as non-Hodgkin's lymphoma. The developer is ImmunityBio (formerly NantKwest), which has advanced this product into Phase 1 clinical trials for various forms of B-cell lymphoma[1][3][4][8].
- Brand names
- CD19-t-haNKCD-19-t-haNKCD 19-t-haNK
- Other names
- CD19 t-haNKCD-19 t-haNKCD 19 t-haNKCD19 t haNKCD-19 t haNKCD 19 t haNK
02
Targets
IgG1 Fc (Immunoglobulin G1 Fc region)CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on CD19t-haNK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19t-haNK.